PubMed

Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes.

Moran A, Phillips J, Milla C.

Diabetes Care. 2001 Oct;24(10):1706-10.PMID: 11574430 [PubMed - indexed for MEDLINE]Related articlesFree article

Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.

Owens DR, Luzio SD, Ismail I, Bayer T.

Diabetes Care. 2000 Apr;23(4):518-23.PMID: 10857945 [PubMed - indexed for MEDLINE]Related articlesFree article

Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

Carroll MF, Izard A, Riboni K, Burge MR, Schade DS.

Diabetes Care. 2002 Dec;25(12):2147-52.PMID: 12453952 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.

Ahmed AB, Home PD.

Diabetes Care. 1998 Jan;21(1):32-7.PMID: 9538967 [PubMed - indexed for MEDLINE]Related articlesFree article

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.

Owens DR.

Diabet Med. 1998;15 Suppl 4:S28-36. Review.PMID: 9868989 [PubMed - indexed for MEDLINE]Related articles

Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.

Ahmed AB, Home PD.

Diabetes Care. 1998 Oct;21(10):1707-13.PMID: 9773735 [PubMed - indexed for MEDLINE]Related articlesFree article

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.

Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60.PMID: 14737746 [PubMed - indexed for MEDLINE]Related articles

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.

Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA.

Eur J Endocrinol. 2008 Jan;158(1):35-46.PMID: 18166815 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, Yale JF, Grossman LD.

Clin Ther. 2000 Feb;22(2):222-30.PMID: 10743981 [PubMed - indexed for MEDLINE]Related articles

Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.

Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Mauro L, Chiara DL, Brunetti P, Bolli GB.

Diabetes Care. 1999 May;22(5):795-800.PMID: 10332684 [PubMed - indexed for MEDLINE]Related articlesFree article

Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.

Van Gaal LF, Van Acker KL, De Leeuw IH.

Diabetes Res Clin Pract. 2001 Sep;53(3):141-8.PMID: 11483229 [PubMed - indexed for MEDLINE]Related articles

Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.

Hollingdal M, Sturis J, Gall MA, Damsbo P, Pincus S, Veldhuis JD, Pørksen N, Schmitz O, Juhl CB.

Diabet Med. 2005 Oct;22(10):1408-13.PMID: 16176204 [PubMed - indexed for MEDLINE]Related articles

Optimal administration of lispro insulin in hyperglycemic type 1 diabetes.

Rassam AG, Zeise TM, Burge MR, Schade DS.

Diabetes Care. 1999 Jan;22(1):133-6.PMID: 10333914 [PubMed - indexed for MEDLINE]Related articlesFree article

Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.

Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I.

Diabetes Care. 2001 Jan;24(1):11-5.PMID: 11194214 [PubMed - indexed for MEDLINE]Related articlesFree article

Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis.

Rafii M, Chapman K, Stewart C, Kelly E, Hanna A, Wilson DC, Tullis E, Pencharz PB.

Am J Clin Nutr. 2005 Feb;81(2):421-6.PMID: 15699230 [PubMed - indexed for MEDLINE]Related articlesFree article

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

Damsbo P, Clauson P, Marbury TC, Windfeld K.

Diabetes Care. 1999 May;22(5):789-94.PMID: 10332683 [PubMed - indexed for MEDLINE]Related articlesFree article

Glargine versus NPH insulin in cystic fibrosis related diabetes.

Grover P, Thomas W, Moran A.

J Cyst Fibros. 2008 Mar;7(2):134-6. Epub 2007 Aug 9.PMID: 17692577 [PubMed - indexed for MEDLINE]Related articles

Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.

Cozma LS, Luzio SD, Dunseath GJ, Underwood PM, Owens DR.

Diabetes Care. 2005 May;28(5):1001-7.PMID: 15855557 [PubMed - indexed for MEDLINE]Related articlesFree article

Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.

Rosak C, Hofmann U, Paulwitz O.

Diabetes Nutr Metab. 2004 Jun;17(3):137-42.PMID: 15334790 [PubMed - indexed for MEDLINE]Related articles